Absci Corp is projected to report a consensus revenue of $0.90 million and an EPS of -$0.18 for the second quarter of 2026, with its stock trading at $8.93 against an average analyst price target of $13.43.
Investors are primarily focused on clinical pipeline progress, particularly for ABS-201, the company's lead AI-designed antibody which recently entered multiple ascending dose trials for hair loss and endometriosis.
The reporting period follows a pivotal $100 million capital raise led by Eli Lilly, which significantly de-risked the balance sheet and extended the cash runway into 2028. Analysts are looking for further evidence that the company's generative AI platform can successfully translate into de-risked clinical candidates and drive broader partnership momentum.